The clinical significance of antinucleolar antibodies

Khan, Sujoy; Alvi, A.; Holding, Stephen; Kemp, Monica; Raine, D; Doré, P.; Sewell, William A.

doi:10.1136/jcp.2007.049692

Cited by 5 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, it is well established that the centromere staining pattern is primarily associated with the limited cutaneous form of SSc (also referred to as the CREST syndrome) [8, 93]. Additional examples are the association of the homogenous IIF pattern with SLE and nucleolar IIF pattern with SSc [37], although these generalizations have not been observed in all studies [94] (most likely attributed to different pretest probabilities). Interestingly, antibodies to dense fine speckled 70 (DFS70), also known as LEDGF (lens epithelium-derived growth factor), which generate a DFS IIF pattern on HEp-2 cells were not commonly observed in AARDs [82, 95–102].…”

Section: Screening and Profile Assays For Ana Detectionmentioning

confidence: 99%

Current Concepts and Future Directions for the Assessment of Autoantibodies to Cellular Antigens Referred to as Anti-Nuclear Antibodies

Mähler

Meroni

Bossuyt

et al. 2014

Journal of Immunology Research

159

151

View full text Add to dashboard Cite

The detection of autoantibodies that target intracellular antigens, commonly termed anti-nuclear antibodies (ANA), is a serological hallmark in the diagnosis of systemic autoimmune rheumatic diseases (SARD). Different methods are available for detection of ANA and all bearing their own advantages and limitations. Most laboratories use the indirect immunofluorescence (IIF) assay based on HEp-2 cell substrates. Due to the subjectivity of this diagnostic platform, automated digital reading systems have been developed during the last decade. In addition, solid phase immunoassays using well characterized antigens have gained widespread adoption in high throughput laboratories due to their ease of use and open automation. Despite all the advances in the field of ANA detection and its contribution to the diagnosis of SARD, significant challenges persist. This review provides a comprehensive overview of the current status on ANA testing including automated IIF reading systems and solid phase assays and suggests an approach to interpretation of results and discusses meeting the problems of assay standardization and other persistent challenges.

show abstract

Section: Screening and Profile Assays For Ana Detectionmentioning

confidence: 99%

Current Concepts and Future Directions for the Assessment of Autoantibodies to Cellular Antigens Referred to as Anti-Nuclear Antibodies

Mähler

Meroni

Bossuyt

et al. 2014

Journal of Immunology Research

159

151

View full text Add to dashboard Cite

show abstract

“…For example, the IF pattern associated with the Golgi complex may be elicited by autoantibodies to several of the Golgi constituents, such as giantin/macrogolgin/GCP372, golgin-245/p230, GMAP-210, golgin-160/GCP170, golgin-95/GM130 and golgin-97 [ 5–10 ]. The IF pattern associated with the nucleolus may be elicited by autoantibodies to several nucleolar constituents, such as Th/To, fibrillarin, NOR90 (nucleolar organizing region-90), RNA polymerase I and nucleolin, involved in various stages of ribosomal biosynthesis and processing [ 11–13 ]. Therefore, the ANA-HEp-2 IF pattern may provide hints on the autoantibody specificity, but in general additional tests are required for the definite autoantibody identification.…”

Section: Introductionmentioning

confidence: 99%

Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern

et al. 2009

View full text Add to dashboard Cite

Objectives. To report on a novel IIF pattern specifically associated with antibodies to DNA topo I.Methods. A novel compound IF pattern, designated Scl-70 pattern, was characterized in routine ANA-HEp-2 IIF screening. Within the last 3 years, all serum samples presenting the Scl-70 pattern at the ANA-HEp2 IIF screening were tested for anti-topo I reactivity. Conversely, 16 serum samples with known anti-topo I reactivity and affinity-purified anti-topo I antibody preparations were tested for the Scl-70 pattern.Results. The Scl-70 pattern comprised the staining of five cellular regions: nucleus, nucleolus and cytoplasm in interphase cells; nucleolar organizing region (NOR) and chromosomes in mitotic cells. All 81 serum samples selected as Scl-70 pattern reacted with topo I. All 16 anti-topo I samples and antibody preparations reproduced the Scl-70 pattern. This compound IF pattern was consistently observed in different commercial HEp-2 cell slides and in home-made slides with HEp-2 cells and human fibroblasts fixed with alternative protocols. Double IIF experiments demonstrated the co-localization of topo I and human upstream binding factor at the NOR.Conclusions. The Scl-70 pattern belongs to the group of compound IF patterns that hold strong association with the respective autoantibody specificities, such as that observed with centromere protein F (CENP-F) and nuclear mitotic apparatus-1 (NuMA-1) protein. The identification of the Scl-70 pattern at routine ANA-HEp-2 IIF screening may lead to implementation of specific tests for the identification of anti-topo I antibodies. In addition, the Scl-70 pattern outlines cellular domains other than those previously reported for topo I, which is of interest for further understanding the roles of this enzyme in cell biology.

show abstract

“…Enfin, pour 20 à 30 % de ces patients des autoAc dirigés contre le nucléole des cellules sont retrouvés. Ces Ac anti-nucléolaires (AANuc) ont été initialement associés aux ScS mais ils sont actuellement négligés au prétexte qu'ils manquent de sensibilité [4]. Toutefois, la caractérisation des cibles des AANuc associée au développement d'examens spécifiques a conféré à ces autoAc un regain d'intérêt [5].…”

Section: Introductionunclassified

Quel est l’intérêt de la recherche des anticorps anti-nucléolaires dans la sclérodermie systémique ?

Comacle

Padelli

Renaudineau

et al. 2011

Immuno-analyse & Biologie Spécialisée

View full text Add to dashboard Cite

The clinical significance of antinucleolar antibodies

Abstract: Neither the presence nor subtype of ANoA is specific for systemic sclerosis. Laboratory comments appended to results should reflect this fact.

Cited by 5 publications

References 13 publications

Current Concepts and Future Directions for the Assessment of Autoantibodies to Cellular Antigens Referred to as Anti-Nuclear Antibodies

Current Concepts and Future Directions for the Assessment of Autoantibodies to Cellular Antigens Referred to as Anti-Nuclear Antibodies

Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern

Quel est l’intérêt de la recherche des anticorps anti-nucléolaires dans la sclérodermie systémique ?

Contact Info

Product

Resources

About